Skip to main content

Erenumab Dosage

Medically reviewed by Last updated on Nov 13, 2022.

Applies to the following strengths: aooe 70 mg/mL; aooe 140 mg/mL

Usual Adult Dose for Migraine Prophylaxis

70 mg subcutaneously once a month

  • Some patients may benefit from 140 mg subcutaneously once a month

Use: For the preventative treatment of migraine.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

No adjustment recommended

Dose Adjustments

Elderly: No specific recommendations, however, in general, dose selection should be cautious, generally starting at the low end of the dosing range.



  • Serious hypersensitivity to the active substance or any product excipients; anaphylaxis and angioedema have occurred.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:

  • For subcutaneous use only
  • Administer subcutaneously in the abdomen, thigh, or upper arm; do not inject into areas where the skin is tender, bruised, red, or hard
  • Patients/caregivers should be trained to properly administer using the single-dose prefilled autoinjector or single-dose prefilled syringe

Storage requirements:
  • Store refrigerated at 2C to 8C (36F to 46F) in the original container to protect from light; do not freeze
  • Once removed from refrigerator, keep at room temperature (up to 25C [77F]) in the original carton and use within 7 days; discard unused product kept at room temperature for more than 7 days

Reconstitution/preparation techniques:
  • Prior to administration, allow drug to sit at room temperature for at least 30 minutes (protect from direct sunlight); do not warm by using a heat source such as hot water or a microwave
  • Do not shake

  • The needle shield within the white cap of the prefilled autoinjector and gray needle cap of the prefilled syringe contain dry natural rubber (a derivative of latex); this may cause allergic reactions in individuals sensitive to latex.
  • In clinical trials, doses of 70 mg and 140 mg were compared to placebo; drug-treatment with both doses demonstrated statistically significant improvements compared to placebo; additionally, patients receiving 140 mg/month showed some improvement over the 70 mg/month dose, although doses were not titrated up nor directly compared.

  • Monitor for severe constipation
  • Monitor for hypertension

Patient advice:
  • Patients should be instructed to read the US FDA-approved Patient Information and Instructions for Use.
  • Patients should receive instruction on proper subcutaneous administration technique.
  • Patients should be instructed to seek immediate medical attention if they experience any symptoms of a serious or severe hypersensitivity reaction, severe constipation, and/or hypertension or worsening of preexisting hypertension.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.